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Background: Triple-negative breast cancers (TNBC) are heterogeneous cancers with poor prognosis. We aimed to determine the
clinical relevance of membrane type-4 matrix metalloproteinase (MT4-MMP), a membrane type matrix metalloproteinase that
interacts with epidermal growth factor receptor (EGFR) overexpressed in 450% of TNBC.
Methods: We conducted a retrospective immunohistochemical analysis on human TNBC samples (n¼ 81) and validated our
findings in in vitro and in vivo assays.
Results: Membrane type-4 matrix metalloproteinase and EGFR are produced in 72.5% of TNBC samples, whereas those proteins
are faintly produced by healthy tissues. Unexpectedly, tumour relapse after chemotherapy was reduced in samples highly positive
for MT4-MMP. Mechanistically, this is ascribed to a higher sensitivity of MT4-MMP-producing cells to alkylating or intercalating
chemotherapeutic agents, as assessed in vitro. In sharp contrast, MT4-MMP expression did not affect tumour cell sensitivity to
paclitaxel that interferes with protease trafficking. Importantly, MT4-MMP expression sensitised cancer cells to erlotinib, a tyrosine
kinase EGFR inhibitor. In a pre-clinical model, the growth of MT4-MMP overexpressing xenografts, but not of control ones, was
reduced by epirubicin or erlotinib. The combination of suboptimal drug doses blocked drastically the growth of MT4-MMP-
producing tumours.
Conclusions: We demonstrate that MT4-MMP defines a sub-population of TNBC sensitive to a combination of DNA-targeting
chemotherapeutic agents and anti-EGFR drugs.
Breast cancer is a highly prevalent cancer in women around the
world (Torre et al, 2015). According to gene expression, six main
intrinsic molecular subtypes of breast cancers are known: luminal
A (HER2 negative), luminal B (triple-positive tumours), human
epidermal growth factor receptor 2 (HER2) enriched, basal-like or/
and triple-negative breast cancer, normal breast-like group and
claudin low (Perou et al, 2000; Sorlie et al, 2001; Carey et al, 2006;
Herschkowitz et al, 2007). Triple-negative breast cancers (TNBC)
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representing 15% of breast cancers, are defined by the lack of
expression of three receptors: oestrogen receptor, progesterone
receptor and HER2. Triple-negative breast cancers are closely
associated to basal-like breast cancers characterised by the
expression of basal cytokeratin (CK) 5/6, CK14 and CK17.
Bertucci et al (2008) reported that 71% of TNBC are found to be
basal-like, whereas 77% of basal-like cancers are triple-negative.
Triple-negative breast cancers are associated with aggressive
features and poor clinical outcomes without efficient hormonal
or targeted treatment options. Patients diagnosed with TNBC have
a higher risk of relapse within 5 years than patients treated for
other breast cancer subtypes (Bauer et al, 2007). Epidermal growth
factor receptor (EGFR) is overexpressed in450% of TNBC (Carey
et al, 2010). Importantly, the rate of mutation for this receptor in
breast cancer is low (10%) and is found mainly in Asian
populations (Teng et al, 2011). Unfortunately, anti-EGFR-targeted
therapy using antibodies (cetuximab; Carey et al, 2012; Baselga
et al, 2013) or tyrosine kinase inhibitors (TKI; erlotinib, dasatinib)
(Finn et al, 2011; Layman et al, 2013) in combination with
chemotherapies were globally disappointing in clinical trials of
TNBC (Yadav et al, 2014). Some clinical activity has been observed
with immunotherapy (Nanda et al, 2016) and many clinical trials
are ongoing in this field (Collignon et al, 2016) but no
immunotherapy agent is currently approved for TNBC treatment.
Therefore, the development of new strategies targeting TNBC or
biomarker for a better patient stratification for conventional or
targeted treatments is crucially needed.
We have recently identified the membrane type-4 matrix
metalloproteinase (MT4-MMP or MMP17) as a new EGFR
partner (Paye et al, 2014). Membrane type-4 matrix metallopro-
teinase belongs to the family of MT MMP that are tethered to the
cell membrane through a trans-membrane domain (MT1-MMP,
MT2-MMP, MT3-MMP and MT5-MMP) or a glycosylpho-
sphatidylinositol anchor (MT4-MMP and MT6-MMP). Although
the involvement of MMPs in cancer progression is well recognised
and documented (Kessenbrock et al, 2010; Noel et al, 2012),
only a few clinical and experimental studies report on MT4-MMP
roles in cancer. Among the MMP family, MT4-MMP displays
unique features and contributes to different steps of cancer
progression through proteolytic and non-proteolytic functions
(Chabottaux et al, 2006, 2009; Host et al, 2012; Paye et al, 2014).
Membrane type-4 matrix metalloproteinase internalisation and
recycling rely on a unique CLIC/GEEK pathway dependent on cdc-
42 (Truong et al, 2016). In an experimental setting, MT4-MMP
overexpression stimulated tumour growth, angiogenesis and
lung metastases (Chabottaux et al, 2006, 2009; Paye et al, 2014).
The MT4-MMP impact on haematogenous metastatic dissemina-
tion is related to its capacity to remodel blood vasculature in a
proteolytic-dependent manner (Host et al, 2012). In line with these
findings, MT4-MMP has also been reported to play a significant
role in hypoxia-mediated metastasis and to be an important
prognostic indicator in patients with head and neck or gastric
cancer (Huang et al, 2009; Wang et al, 2015). Beyond promoting
cell invasiveness, MT4-MMP overexpression also endows
TNBC cells with a higher proliferation rate (Paye et al, 2014).
Indeed, in a non-proteolytic manner, MT4-MMP interferes with
the EGFR pathway and promotes EGFR activation in response to
its ligands.
In this study, we investigated the clinical relevance of MT4-
MMP/EGFR axis by immunohistochemical (IHC) analyses and
found that MT4-MMP and EGFR expressions were enhanced
in 470% of human TNBC tissues. We also established an
unprecedented link between high MT4-MMP expression and high
progression-free survival (PFS) in TNBC patients. We demonstrate
that MT4-MMP plays a key role in tumour response to alkylating
and intercalating chemotherapeutic drugs, but not to drug target-
ing microtubules. This novel concept is supported by in vitro and
in vivo studies. Importantly, MT4-MMP expression sensitises
tumours to a combination of chemotherapeutic and targeted anti-
EGFR (erlotinib) drugs.
MATERIALS AND METHODS
Immunohistochemistry and analysis of samples. Human TNBC
cancer samples (n¼ 81) and normal breast tissue (n¼ 24) issued
from mammary reduction were provided by the Biobank of the
University Hospital of Lie`ge (University of Lie`ge, Belgium). The
specimen collection and the distribution of human samples to
researchers follow the rules imposed by the current legislation and
the recommendations of the institutional review board (Comite´
d’e´thique Hospitalo-Facultaire Universitaire de Lie`ge), which
approved this study. Human samples were formalin (4%) fixed
and paraffin embedded. The immunostainings of MT4-MMP
and EGFR were performed on adjacent slides. For MT4-MMP
immunohistochemistry, tumour sections (6 mm thick) were
incubated in citrate buffer (DAKO S2031, Santa Clara, CA, USA)
for 1 h at 80 1C. Endogenous peroxidases were subsequently
blocked by 3% H2O2/H2O for 20min, and non specific binding
was prevented by incubation in PBS/10% bovine serum albumin
(Fraction V, Acros Organics, Fair Lawn, NJ, USA) for 1 h. Slides
were first incubated overnight at 4 1C with a rabbit polyclonal anti-
human-MT4-MMP antibody (1/500; AB39028; Abcam, Cam-
bridge, USA) and then with a HRP-conjugated anti-rabbit
secondary antibody (Envision System-Labeled Polymer-HRP,
DAKO, K4003), for 30min, at room temperature. For staining,
3-30 diaminobenzidine hydrochloride (DAKO, K3468) was incu-
bated for 3min. Slides were finally counterstained with haematox-
ylin and mounted with Eukitt medium for microscope observation.
For EGFR staining, antigen retrieval was performed with
EDTA buffer. Slides were incubated with a rabbit monoclonal
anti-EGFR antibody (5B7; 790-4347, Ventana Medical Systems,
Roche, Indianapolis, IN, USA) for 32min, and signal amplification
was achieved by using an amplification kit (760-080, Ventana
Medical Systems, Roche) in a series automated slide strainer
(Discovery XT, Ventana Medical Systems, Roche). Finally, sections
were incubated with universal secondary antibody (760-4205,
Ventana Medical Systems, Roche) for 32min and signal was
detected with DAB Map detection kit (760-124, Ventana Medical
Systems, Roche). Counterstaining was performed with haematox-
ylin II (790-2208, Ventana Medical Systems, Roche). The
specificity of MT4-MMP antibody has been tested on xenografts
of human MDA-MB-231 cell line expressing or not MT4-MMP.
The anti-EGFR antibody is currently used by anatomo-pathologists
in clinical routine. Omission of the first antibody served as
negative control.
The IHC results for EGFR and MT4-MMP were recorded as the
percentage of breast cancer cell number showing a positive
staining. The percentage of breast cancer cells expressing MT4-
MMP or EGFR was determined by a pathologist. Ki67 positivity
was quantified as the percentage of positive nuclear staining of
tumour cells. A cut off of 20% was used for assessing the active
proliferation (Huang et al, 2013). Cytokeratin 5/6 staining was
considered positive when 410% tumour cells were labelled
(Gazinska et al, 2013).
Cell culture. Human TNBC cells (MDA-MB-231) were purchased
from the American Type Culture Collection (ATCC, Manassas,
VA, USA). Cells were grown in DMEM supplemented with 10%
FBS, L-glutamine (2mmol  l), penicillin (100Uml 1) and
streptomycin (100mgml 1), at 37 1C, in a 5% CO2 humid
atmosphere. All culture reagents were purchased from Invitrogen
(Carlsbad, CA, USA). MDA-MB-231 cells were stably transfected
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by electroporation with pcDNA3-neo vector, either empty (control
plasmid, CTRL) or containing the active human full-length MT4-MMP
cDNA (Chabottaux et al, 2009) tagged or not by a FLAG peptide
(DYKDDDDK) after Pro319 (Host et al, 2012). Stable transfectants
were cultured in medium containing 500mgml 1 of G418 (Life
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Figure 1. Immunohistochemical detection of MT4-MMP and EGFR in healthy breast tissues (n¼ 24) and TNBC samples (n¼ 81). (A) Representative
immunostainings of MT4-MMP and EGFR in healthy breast and TNBC samples. (B) Distribution of the percentage of cancer cells with a positive
MT4-MMP or EGFR staining in healthy breasts and TNBC. (C) Proportion of patients with TNBC presenting a double immunostaining (MT4-MMP
þ /EGFRþ ), a single staining of MT4-MMP or EGFR (MT4-MMPþ /EGFR- or MT4-MMP-/EGFRþ ) and a negative staining (MT4-MMP-/EGFR-).
The proportion of patients with a co-localisation of MT4-MMP and EGFR is also represented inside the histogram by the crosshatching area.
***Po0.001.
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In vitro 3-dimensional proliferation assay and DNA quantification.
A first layer of Matrigel mixed with an equal volume of culture medium
without cells was seeded into 48-well plates (120ml per plate). Cells
(104) suspended in medium (100ml) were mixed with cold Matrigel
(100ml) and seeded on the first Matrigel layer. Cells
were grown in DMEM supplemented with 1% FBS, L-glutamine
(2mmol l 1), penicillin (100Uml 1) and daily treated with EGF
(20ngml 1). The different drugs used include erlotinib (CP358774;
LC Laboratories, Woburn, MA, USA), epirubicin, cyclophosphamide,
paclitaxel or cisplatine, which were all kindly provided by the
Pharmacology department of CHU. For drug treatment, cells were
incubated in Matrigel during 24h and the drug was added to the
culture medium every 2 days, at the indicated concentrations. After 7
days, cells were recovered from 3D cultures upon treatment with 200ml
of Dispase (VWR, Radnor, PA, USA), for 2h at 37 1C. After two
washes in PBS, cell pellets were diluted in PBS (1ml) and sonicated.
Fluorimetric DNA titration was performed by measuring fluorescence
in a Spectra Max Gemini Xs (Molecular Devices, Sunnyvale, CA, USA),
at 355nm excitation and 460nm emission. Results are expressed as
percentage of proliferation inhibition of treated cells compared to the
untreated cells (100% corresponding to a complete proliferation
inhibition of treated cells compared to the untreated cells).
In vivo tumourigenicity. The in vivo experiments have been
approved by the ethical committee (Comite´ d’e´thique Hospitalo-
Facultaire Universitaire de Lie`ge). Subconfluent cells were trypsi-
nised, suspended in serum-free medium (5 106 cellsml 1), and
mixed with an equal volume of cold Matrigel (Chabottaux et al,
2006). Cell suspension (106 cells in 400ml) was injected subcuta-
neously into RAG-1 immunodeficient mice at both flanks. Our
laboratory has previously reported that the tumour promoting effect
of MT4-MMP is similarly observed when tumour cells are injected
subcutaneously or in the mammary fat pad (Paye et al, 2014).
Tumour growth was assessed by measuring the length and width of
tumours every 3–4 days. Tumour volumes were estimated using the
formula: lengthwidth2 0.4 (Maillard et al, 2005). When the
tumour volume reached 200mm3, mice were randomised into
different experimental groups (four mice per group). Mice were
intraperitoneally injected with epirubicin (4mgkg 1, twice a week)
and/or orally treated with erlotinib (50mgkg 1, every day). NaCl
0.9% or captisol 6% was used as vehicles for epirubicin and erlotinib,
respectively. When using suboptimal doses of chemotherapeutic
agents (six mice per group), mice were treated with 2mgkg 1 of
epirubicin twice a week and/or 50mgkg 1 of erlotinib every 2 days
when the tumour volume reached 100mm3. In those assays, results
are expressed as relative tumour volume: tumour volume measured
at a specific time point divided by the tumour volume measured at
day 0, which corresponds to the first day of treatment. The results
were presented as the mean of the relative tumour volume for each
experimental group with the s.e.m. Statistical significance was
evaluated by using the two-way repeated ANOVA.
Flow cytometry. MDA-MB-231 (5 105 cells per condition)
expressing MT4-MMP-Flag (Truong et al, 2016) or not were
treated or not with paclitaxel (10, 50 or 100 nM), epirubicin
(100 nM) or erlotinib (100 nM). After 12 h, cells were detached with
Accutase, and fixed and permeabilised with the Cytofix/Cytoperm
kit (554714; BD Biosciences, San Jose, CA, USA) for 40min at 4 1C.
After washing, cells were incubated with a FITC-conjugated mAb
against Flag M2 (1 : 500 dilution, F4049; Sigma, St Louis, MO,
USA) in 1% BSA/PBS, for 1 h at 4 1C. After washing, cells were
analysed by flow cytometry, with 10 000 events (FACS Calibur II;
BD Biosciences). For the membrane staining, we followed the same
procedure and omitted the fixation and permeabilisation. The
median fluorescence intensity of cells treated with paclitaxel was
normalised to that of MDA-MB-231 control cells, and compared to
untreated cells considered as 100%.
Immunofluorescence and confocal microscopy. MDA-MB-231
cells expressing MT4-MMP were grown on 12mm sterile round
glass coverslips. After 24 h of incubation, cells were treated or not
with 10, 50 or 100 nM of paclitaxel. After 12 h, cells were fixed
for 15min in 4% paraformaldehyde and permeabilised for 5min
with 0.25% Triton X-100/PBS, at room temperature. Slides were
blocked in PBS containing 1% BSA and 10% normal goat serum
solution, and incubated with an antibody against MT4-MMP
(1 : 100 dilution, Ab51075; Abcam) and an antibody against alpha 1
Sodium Potassium ATPase referred as a plasma membrane marker
(1/200 dilution, Ab7671; Abcam) in 1% BSA/PBS overnight at 4 1C.
Cells were then incubated with the secondary antibody, that is,
Alexa Fluor 546 goat anti-rabbit IgG (1 : 200 dilution, A11035;
Invitrogen) and Alexa Fluor 488 goat anti-mouse IgG (1 : 1000
dilution, A11029; Invitrogen) in 1% BSA/PBS, for 1 h at 37 1C.
Finally, cells were mounted on slides with Dapi Fluoromount-G
(0100-20; Southern Biotech, Birmingham, AL, USA) and analysed
on an Olympus FV1000 confocal microscope with  60 oil
immersion objective (Olympus America, Waltham, MA, USA).
Statistical analysis. The impact of MT4-MMP and EGFR on the
tumour status (T1-2 vs T3-4), the nodal stage (N0-1 vs N2-3) and
the Ki67 (o20 vs X20%) were assessed using univariate and
multivariate binary logistic regressions. Results were presented
using odds ratios with corresponding 95% confidence intervals.
Table 1. Clinicopathological details of patients
Number of patients 81
Median follow-up 53 months
Median age 60 years
Median progression-free survival 21 months
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The impact of MT4-MMP and EGFR on the stage of the tumour
was evaluated using univariate and multivariate proportional odds
models (ordinal regression). Cumulative odds ratios and respective
95% confidence intervals were estimated. Cox’s proportional odds
models were used to analyse the effect of MT4-MMP and EGFR on
the overall survival (OS) and PFS. Additional analyses were applied
to determine the impact of MT4-MMP on PFS in patients treated
or not with chemotherapy independently. Results were presented
using hazard ratios with corresponding 95% confidence intervals.
Those investigations were depicted graphically using Kaplan–
Meier curve. Results were considered to be significant at the
5% critical level. Analyses were carried out using SAS 9.4 (World
Headquarters and SAS Institute Inc., Cary, NC, USA) and
GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
MT4-MMP and EGFR are both overexpressed in the majority of
TNBC. Immunohistochemical stainings for MT4-MMP and
EGFR were performed on healthy breast tissues (n¼ 24) and
tumour samples issued from the cohort described below. MT4-
MMP and EGFR expressions were represented by the percentage of
cancer cells positive for each immunostaining. Whereas, low MT4-
MMP and EGFR expression was observed in healthy breast, their
expression was increased in TNBC (Figure 1A and B). The
different expression patterns (MT4-MMPþ /EGFRþ , MT4-
MMPþ /EGFR-, MT4-MMP-/EGFRþ and MT4-MMP-/EGFR-)
are illustrated in Figure 1A. Interestingly, 72.5% (59 out of 81) of
TNBC patients expressed MT4-MMP and EGFR together, whereas
25% (20 out of 81) expressed MT4-MMP or EGFR and 2.5% (2 out
of 81) were negative for the both proteins. Among the 72.5% of
TNBC patients who expressed MT4-MMP and EGFR, 79%
displayed common stained areas for both proteins in serial section
of TNBC (Figure 1C).
TNBC cohort and patient characteristics. Clinical and histolo-
gical characteristics of patients (n¼ 81) with TNBC are reported in
Table 1. The patients who have received neoadjuvant treatment
have been excluded from the study. This retrospective cohort
consists of women aged from 27 to 89 years diagnosed between
February 1999 and September 2013 with a median follow-up of 53
months (4.4 years). During the follow-up, 34 (42%) patients
relapsed or presented progressive disease and 30 (37%) died. All
patients had surgery as the upfront treatment option. Most patients
received also adjuvant radiotherapy (59 out of 78, 75.6%) and
chemotherapy (55 out of 79, 69.6%). The majority of patients
receiving adjuvant chemotherapy were treated with the combina-
tion of epirubicin and cyclophosphamide associated or not with
fluorouracile and/or taxane (n¼ 45). The other patients received
CMF (cyclophosphamide methotrexate 5-fluorouracile) (n¼ 5).
The majority of patients were clinical stage 1 (42.5%) and 2
(37.5%), only 20% of samples were stage 3. The half of patients
(44.7%) presented lymph node invasion, but no distant metastases
were observed. Ki67 expression was at least 20% in 63 (79.7%)
patients. The half of patients (54.3%) expressed CK5/6, a marker of
basal-like tumours.
We next searched for putative association between MT4-MMP
and EGFR expressions, and several clinicopathological variables in
TNBC patients (Table 2). The statistical analyses were assessed by
considering MT4-MMP and EGFR expression as continuous
variables without using any arbitrary cut offs. There was no
significant association between MT4-MMP or EGFR expression
with any of the clinicopathological features evaluated (tumour
size, nodal status, stage or Ki67). Similar results were observed
Table 2. Correlation of MT4-MMP and/or EGFR staining in TNBC with clinicopathological parameters using logistic regression
and proportional odds model
OR (95% CI) crude OR (95% CI) EGFR and MT4-MMP adjusted
Parameters EGFR MT4-MMP EGFR MT4-MMP
Tumours
T1-T2 1.01 (0.99–1.03) 1.01 (0.99–1.04) 1.01 (0.99–1.03) 1.01 (0.98–1.04)
T3-T4 P¼ 0.41 P¼0.42 P¼ 0.39 P¼ 0.43
Nodes
N0-N1 1.01 (0.98–1.03) 0.97 (0.94–1.01) 1.01 (0.98–1.03) 0.97 (0.94–1.01)
N2-N3 P¼ 0.62 P¼0.10 P¼ 0.66 P¼ 0.094
Stages
1
2 1.00 (0.99–1.01) 0.99 (0.98–1.01) 1.00 (0.99–1.01) 1.00 (0.99–1.02)
3 P¼ 0.98 P¼0.71 P¼ 0.97 P¼ 0.60
Ki67
o20% 1.00 (0.99–1.03) 1.00 (0.98–1.02) 1.00 (0.99–1.03) 0.99 (0.98–1.02)
X20% P¼ 0.30 P¼0.91 P¼ 0.31 P¼ 0.75
Abbreviations: CI¼ confidence interval; EGFR¼ epidermal growth factor receptor; MT4-MMP¼membrane type-4 matrix metalloproteinase; OR¼odds ratio; TNBC¼ triple-negative breast
cancers.
Table 3. Multivariate analyses of overall survival and
progression-free survival by Cox’s proportional hazard model
HR 95% CI P-value
Complete cohort
Overall survival
EGFR 1.01 0.99–1.03 0.1848
MT4-MMP 0.98 0.95–1.00 0.0464*
Progression-free survival
EGFR 1.03 1.01–1.05 0.0071**
MT4-MMP 0.97 0.94–0.99 0.0040**
Patients treated with chemotherapy
Overall survival
MT4-MMP 0.96 0.91–1.01 0.0802*
Progression-free survival
MT4-MMP 0.93 0.88–0.98 0.0059**
Patients untreated with chemotherapy
Overall survival
MT4-MMP 1.00 0.94–1.06 0.9154
Progression-free survival
MT4-MMP 1.02 0.97–1.06 0.5232
Abbreviations: CI¼ confidence interval; EGFR¼ epidermal growth factor receptor; HR¼
hazard ratio; MT4-MMP¼membrane type-4 matrix metalloproteinase. *Po0.05, **Po0.01.
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when evaluating the impact of MT4-MMP expression by adjust-
ing the EGFR variable, and vice versa (Table 2). In conclusion,
MT4-MMP and EGFR were not associated to the tumour
size, nodal status, stage or Ki67, whether analysed separately or
together.
MT4-MMP expression influences TNBC patients’ survival and
progression-free survival. In our cohort, EGFR expression is
correlated with a poor PFS (P¼ 0.0071) but not with a shorter OS
(P¼ 0.1848). Surprisingly, MT4-MMP expression was associated
with a significant better OS (P¼ 0.0464) and PFS (P¼ 0.0040)
(Table 3). The impact of MT4-MMP on OS and PFS was not
highlighted for patients untreated with chemotherapy suggesting
that the benefice of MT4-MMP on OS and PFS was linked to the
response of patients to chemotherapy (Table 3). Indeed, in the
cohort of patients treated with chemotherapy, MT4-MMP was still
linked to a better OS (P¼ 0.0802) and PFS (P¼ 0.0059). The
impact of MT4-MMP expression on PFS in patients treated or not
with chemotherapy is illustrated by the Kaplan–Meier curves
applying a cut off of 50%, which corresponded to the cut off from
which a significant impact of MT4-MMP on PFS was observed
(Figure 2).
MT4-MMP expression sensitises TNBC cells to chemotherapies
in vitro. Our clinical data prompted us to conduct an in vitro
study to assess whether MT4-MMP expression could influence
the response of TNBC cells to chemotherapeutic agents. The
proliferation rate of TNBC MDA-MB-231 cells overexpressing
MT4-MMP (MT4-MMP cells) or not (CTRL cells) was evaluated
in a 3D-matrigel assay to better mimic the in vivo situation, as
previously described (Paye et al, 2014). Cells were treated with
increasing concentrations of different chemotherapeutic agents.
Four chemotherapeutic agents currently used in the clinic were
evaluated: epirubicin, cyclophosphamide, cisplatin and paclitaxel.
Interestingly, the overexpression of MT4-MMP conferred a
therapeutic benefit to epirubicin, cyclophosphamide and cisplatin
(Figure 3A–C). Indeed, the proliferation of MDA-MB-231 cells
overexpressing MT4-MMP was more affected in the presence of
these drugs compared to control cells. A higher cell proliferation
inhibition was achieved with MDA-MB-231 overexpressing MT4-
MMP than non-expressing cells: 6.5-fold for epirubicin at 1mM,
13.5-fold for cyclophosphamide at 0.01mM and 1.5-fold for
cisplatin at 0.1 mM. Surprisingly, MDA-MB-231 cells overexpres-
sing MT4-MMP did not show any additional therapeutic benefit to
paclitaxel. Cancer cell response to paclitaxel was similar in MDA-
MB-231 overexpressing MT4-MMP or not (Figure 3E). Paclitaxel
inhibits microtubule depolymerisation and has been described to
affect the secretion and the activity of MMP-2 and MMP-9
(Schnaeker et al, 2004). Accordingly, we found that MT4-MMP
trafficking was disturbed upon paclitaxel treatment. Proportionally
to paclitaxel doses, the amount of MT4-MMP present at the cell
membrane was decreased and the enzymes accumulated in the
cytoplasm. The loss of MT4-MMP at the membrane and its
accumulation in the cytoplasm was confirmed by a confocal
microscopy analysis of MT4-MMP and alpha 1 NaK-ATPase,
referred as a plasma membrane marker (Oldridge et al, 2013;
Figure 3F). A reduced availability of MT4-MMP at the cell surface
induced by paclitaxel could reduce its interaction with EGFR
abolishing, thereby its proliferative effect of MT4-MMP and cell
sensitisation to paclitaxel. In reverse, the MT4-MMP at the
membrane and the total MT4-MMP was not disturbed by
epirubicin (Figure 3G). All together, we concluded that MT4-
MMP expression sensitises TNBC cells in vitro to epirubicin,
cyclophosphamide and cisplatin, but not to paclitaxel.
MT4-MMP expression sensitises TNBC cells to erlotinib
in vitro. Although EGFR overexpression is observed in more
than 50% of TNBC, its inhibition alone or in combination with
chemotherapy has resulted in minimal clinical benefit. Therefore, it
is crucial to identify a biomarker to select TNBC patients
susceptible to respond to anti-EGFR treatment. Accordingly, we
extended our work to erlotinib, a TKI. In the 3D-matrigel assay,
the proliferation of MDA-MB-231 overexpressing MT4-MMP was
more affected by erlotinib than that of control cells (Figure 3D).
At 1 mM of erlotinib, the inhibition of cell proliferation was
twice higher in the presence of MT4-MMP expression (Po0.01).
The MT4-MMP at the membrane and the total MT4-MMP was
not disturbed by erlotinib or the combination of erlotinib and
epirubicin (Figure 3G).
MT4-MMP expression sensitises TNBC xenografts to epirubicin
and erlotinib. To validate the in vitro findings, we next tested the
impact of MT4-MMP expression on in vivo response of tumours
to a chemotherapeutic agent (epirubicin) and erlotinib, in
monotherapies and in combination treatments. As previously
described, MT4-MMP xenografts grew faster than control
xenografts (Figure 4A). Mice bearing xenograft of MDA-MB-231
cells overexpressing or not MT4-MMP were treated with 4mg kg-1
of epirubicin twice a week, 50mg kg 1 of erlotinib once a day or
with the combination of the two treatments. Upon epirubicin
or erlotinib treatment, the growth of MT4-MMP tumour was
stabilised (Figure 4B). In sharp contrast, the growth of control














HR = 1.60 (0.57 – 4.46)
Logrank P = 0.3694
HR = 4.71 (1.64 –13.57)






























Figure 2. Kaplan–Meier progression-free survival (PFS) curves from patients untreated by chemotherapy (n¼ 24) and TNBC patients treated
with chemotherapy (n¼ 47) according the MT4-MMP expression. (A) No significant difference in PFS was observed in patients untreated with
chemotherapy. (B) A significant difference in PFS was observed in patients treated with chemotherapy when more than 50% of breast cancer cells
expressed MT4-MMP. Note: 95% confidence interval is represented between the parentheses. HR, hazard ratio.
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Figure 3. MT4-MMP overexpression sensitises MDA-MB-231 cells to alkylating and intercalating chemotherapies, and erlotinib but not to
paclitaxel. MDA-MB-231 cells overexpressing MT4-MMP (MT4-MMP) or not (control) were incubated in a 3D matrix (Matrigel). Cell proliferation
was assessed by DNA measurement after 7 days of culture in the presence of different concentrations of epirubicin (A), cyclophosphamide (B),
cisplatin (C), erlotinib (D) and paclitaxel (E) as indicated. Results are expressed as percentage of inhibition. (F) Paclitaxel disturbs the intracellular
trafficking of MT4-MMP. FACS analysis demonstrated that MT4-MMP was decreased at the cell surface and accumulated in the cytoplasm (total
MT4-MMP). A representative illustration of MT4-MMP (in red) and NaK-ATPase (green) stainings observed by confocal microscopy is shown below
the graph, for each paclitaxel concentration used. The blue staining corresponds to the nucleus stained with Dapi Fluoromount-G. (G) The
intracellular trafficking of MT4-MMP was not disturbed by the treatment of epirubicin or erlotinib or the combination. FACS analysis demonstrated
that the total MT4-MMP and the MT4-MMP at the membrane was not modified by these drugs. *Po0.05; **Po0.01.
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xenografts was not affected by epirubicin or erlotinib and was
similar to that of tumour treated with the vehicle (Figure 4C).
In line with in vitro data, MT4-MMP tumours were thus more
sensitive to epirubicin and erlotinib monotherapies (Figure 4D).
Due to a high toxicity of epirubicin and erlotinib combination
leading to mice death, we next used suboptimal doses of epirubicin
and erlotinib. In those conditions, no effect of the monotherapy
was observed on the tumour growth of MT4-MMP or control
xenografts. Interestingly, the combination of epirubicin and
erlotinib treatments led to a drastic inhibition of the growth of
MT4-MMP xenografts, but did not affect the progression of
control tumours (Figure 5A and B). The comparison of the tumour
volume reached at the end of the assay (Figure 5C) revealed
a clear improved response to drug combination by MT4-MMP
expressing xenografts as compared to control tumours, as well
as to monotherapies. Membrane type-4 matrix metalloproteinase
expression endows to the tumour with a higher sensitivity to
erlotinib combined with epirubicin.
DISCUSSION
We here established an unprecedented link between a strong
MT4-MMP expression and an increased PFS in patients treated by
chemotherapy. We identified MT4-MMP as a marker of tumour
response to alkylating or intercalating agents used in monoche-
motherapy, or combined with erlotinib. This is supported by
(1) clinical data using a retrospective cohort of TNBC patients
subjected or not to chemotherapy; (2) in vitro data in a 3D model
demonstrating a higher sensitivity of TNBC cells to DNA-targeting
drugs, but not to a cytoskeletal-targeting drug and finally (3) pre-
clinical data in TNBC xenografts demonstrating the efficacy of a
combination of suboptimal doses of DNA-interfering drug and
erlotinib to completely block tumour growth.
Human MT4-MMP is a pro-tumoural protein expressed by
cancer cells that promotes metastatic dissemination through its
catalytic function (Host et al, 2012) and tumour cell proliferation
by interfering with EGFR (Chabottaux et al, 2006; Paye et al, 2014).
We found that MT4-MMP and EGFR were overexpressed in
470% of TNBC samples. In line with the literature, EGFR
expression was not associated with clinicopathological factors
(tumour size, lymph node invasion, tumour stage or Ki67; Rao
et al, 2013; Sood and Nigam, 2014), but was linked to a poor PFS
(Viale et al, 2009). Although MT4-MMP was not associated to
clinicopathological features, its expression and co-localisation with
EGFR in 79% of TNBC patients might affect patient outcome and
response to chemotherapy. Indeed, patients developing tumours
with more than 50% of MT4-MMP-positive cells showed a better
PFS when treated with chemotherapy. In contrast, MT4-MMP
expression was not associated to PFS in untreated patients. Given
the reported mitogenic effect of this protease (Chabottaux et al,
2006; Paye et al, 2014), MT4-MMP overexpression in TNBC
cells could make them more sensitive to DNA-targeting agents.
This concept is supported by our data showing increased TNBC
cell responsiveness to alkylating (cyclophosphamide, cisplatin) or
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Figure 4. MT4-MMP overexpression sensitises MDA-MB-231 xenografts to epirubicin and erlotinib. (A) Tumour growth of MDA-MB-231
cells overexpressing or not MT4-MMP injected in RAG-1 immunodeficient mice. (B, C) Relative tumour growth of MDA-MB-231 xenografts
overexpressing (B) or not (C) MT4-MMP treated with vehicle (n¼ 4), epirubicin (n¼4) or erlotinib (n¼ 4). Mice were intraperitoneally injected with
epirubicin (4mg kg 1) twice a week or orally treated with erlotinib (50mgkg 1) once a day. NaCl 0.9% and captisol 6% were used as control for
epirubicin and erlotinib, respectively. Tumour volume was measured twice a week. (D) Comparison of the relative tumour growth of control and
MT4-MMP tumours treated with epirubicin or erlotinib at the end of the assay (day 21). Values are means±s.e.m. *Po0.05; **Po0.01;
***Po0.001.
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of response to paclitaxel could be ascribed to the impact of
microtubule disruption on MT4-MMP availability at the cell
surface. Indeed, MT4-MMP internalisation dynamics was recently
reported showing that the enzyme stays 45min at the cell surface
before being internalised and either auto-degraded or recycled to
the cell surface (Truong et al, 2016). It is thus not surprising that
compounds that can affect its trafficking and internalisation
dynamics could also affect its interaction with EGFR, and hamper
its impact on cell proliferation.
Despite a good initial response of TNBC to chemotherapy,
metastatic relapse occurs at higher rates compared to other breast
cancer subtypes (Isakoff, 2010; O’Reilly et al, 2015). Epidermal
growth factor receptor overexpression by most TNBC offers an
opportunity that could be explored for an effective targeted
therapy. However, up to now, clinical trials using anti-EGFR
antibodies in TNBC patients did not show any benefit in terms
of PFS. These disappointing results with cetuximab could be
explained, at least partly, by the contribution of compensatory
pathways of TK signalling, and/or of unknown factors interfering
with the EGFR pathway. Here we provide in vivo evidence of
effective response of MT4-MMP and EGFR expressing tumours to
erlotinib. Membrane type-4 matrix metalloproteinase expression
conferred to xenografts, a better response to epirubicin and
erlotinib alone (monotherapy) and more importantly, to the
combination of these drugs at suboptimal doses. This is in line with
our previous in vitro data showing that erlotinib blocked drastically
the proliferation of MT4-MMP expressing cells in 3D cultures. In
contrast, only a partial inhibition of cell proliferation was achieved
with cetuximab. Thus, MT4-MMP endows tumour cells with a
higher sensitivity to TKIs that act intracellularly than to antibodies
exerting an extracellular effect. This could explain why cetuximab
treatment was inefficient to treat TNBC patients despite the
presence of MT4-MMP. These innovative findings hold promise
for the use of TKI in selected TNBC overexpressing MT4-MMP.
Altogether, these findings provide the first clinical and molecular
evidence for MT4-MMP role in TNBC. These innovative findings
hold promise for the use of TKI (erlotinib) combined with DNA-
interfering chemotherapeutic agents in selected TNBC overexpressing
MT4-MMP and EGFR. The MT4-MMP/EGFR axis emerges as a new
valuable pathway that could have a striking impact on TNBC cancer
patients expressing these two molecules.
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Figure 5. MT4-MMP overexpression sensitises MDA-MB-231 xenografts to a combination of epirubicin and erlotinib. (A, B) Relative tumour
growth of MDA-MB-231 xenografts overexpressing or not MT4-MMP treated with vehicle (n¼ 6), epirubicin (n¼6), erlotinib (n¼6) or a
combination of the two drugs (n¼6). Mice were intraperitoneally injected with epirubicin (2mgkg1) twice a week and/or were orally treated with
erlotinib (50mgkg 1) three times a week. (C) Comparison of relative tumour growth of control and MT4-MMP tumours treated with epirubicin
and/or erlotinib at day 25. Values are means±s.e.m. *Po0.05; **Po0.01; ***Po0.001.
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